Wisconsin Division of Public Health Disease Surveillance Manual (EpiNet, February 2005)

I. IDENTIFICATION

A. CLINICAL DESCRIPTION: An illness with acute onset of unilateral or bilateral tender, self-limited swelling of the parotid or other salivary gland, lasting ³ 2 days, and without other apparent cause (as reported by a health professional).

B. REPORTING CRITERIA: Clinical diagnosis.

C. LABORATORY CRITERIA FOR CONFIRMATION:

• Positive serologic test for mumps IgM antibody, OR
• Significant rise between acute and convalescent titers in serum mumps IgG antibody
• Isolation of mumps virus from clinical specimen, OR
• Detection of virus by reverse transcription polymerase chain reaction (RT-PCR)

D. WISCONSIN CASE DEFINITION: A case that is laboratory confirmed or that meets the clinical case description and is epidemiologically linked to a confirmed or probable case. A laboratory confirmed case does not need to meet the clinical case definition.

II. ACTIONS REQUIRED / PREVENTION MEASURES

A. WISCONSIN DISEASE SURVEILLANCE CATEGORY II: Report to the patient's local health officer on an Acute and Communicable Disease Case Report (DPH 4151) or other means within 72 hours of the identification of a case or suspected case.

B. EPIDEMIOLOGY REPORTS REQUIRED:

• Acute and Communicable Diseases Case Report (DPH 4151).
• Mumps Surveillance Worksheet (Mumps CDC).

C. PREVENTION MEASURES:

• Routinely administer initial dose of MMR (measles, mumps and rubella) vaccine at
• 12-15 months of age and second dose at school entry (4 - 6 years of age).
• Special effort should be made to immunize before puberty, especially males, with no definite history of mumps or mumps immunization.

D. PUBLIC HEALTH INTERVENTIONS:

• Respiratory isolation and private room for nine days from onset of swelling; less if swelling has subsided. Exclusion form school or workplace until nine days after onset of parotitis if susceptible contacts (those not immunized) are present.
• Exclude susceptible contacts from school or the workplace from the 12th through the 25th day after exposure if other susceptibles are present.
• Immunize susceptible contacts. Although this may not prevent disease after exposure to natural mumps, those who did not develop disease would be protected against infection from subsequent exposures. IG is not effective and not recommended.

III. CONTACTS FOR CONSULTATION

A. BCDP / IMMUNIZATION PROGRAM: (608) 266-3031.

B. REGIONAL STAFF: See Epinet Introduction: “REGIONAL OFFICE CONTACTS”.

C. WSLH /

1. SEROLOGY: (608) 262-0248
2. CULTURE: (608) 262-3185

 IV. RELATED REFERENCES  

1. "Mumps" DPH Disease Fact Sheet Series: View a list of all current Communicable Disease Fact Sheets

2. Heymann DL, ed. MUMPS. Control of Communicable Diseases Manual. 18 th ed. Washington , DC : American Public Health Association, 2004:376-379.

3. Pickering LK, ed. Mumps. In: Red Book: 2003 Report of the Committee on Infectious Diseases. 26 th ed. Elk Grove Village , IL : American Academy of Pediatrics, 2003:439-443.

4. Measles, Mumps and Rulella – Vaccine Use and Strategies for Elimination of Measles, Rubella and Congenital Rubella Syndrome and Control of Mumps – Recommendations of the Advisory Committee on Immunization Practices (ACIP), MMWR, 1998; 47 (RR-8):1-57.

V. DISEASE TREND